Posts Tagged ‘HPS2-THRIVE’

RSS

July 16th, 2014

HPS2-THRIVE: The Final Chapter in the Niacin Story?

and

Findings from HPS2-THRIVE raise uncomfortable questions for physicians.


March 9th, 2013

HPS2-THRIVE: A ‘Disappointing But Clear’ Result

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. The results of HPS2-THRIVE were “disappointing but clear,”  said Jane Armitage, who presented the results this morning at the ACC […]


January 15th, 2013

Is HDL Fool’s Gold?

Peter P. Toth offers his perspective on recent trials of niacin, including HPS2-THRIVE and AIM-HIGH.


January 11th, 2013

Merck Starts to Suspend Worldwide Availability of Tredaptive

In the wake of the negative HPS2-THRIVE study announced last month, Merck said today that it was beginning to suspend the worldwide availability of Tredaptive, its combination of extended-release niacin and laropiprant. Merck described its decision as being “aligned” with that of the European Medicines Agency’s  Pharmacovigilance Risk Assessment Committee (PRAC), which recommended on Thursday that drugs containing extended-release niacin and laropiprant should be suspended. The drug […]


January 9th, 2013

Niacin Therapy in the Crossfire

and

William E. Boden, lead investigator of the AIM-HIGH trial, and CardioExchange’s Harlan M. Krumholz debate the current state of research on niacin therapy.


January 4th, 2013

Why Has Niacin Therapy Failed to THRIVE?

and

In the wake of HPS2-THRIVE, John Ryan asks William E. Boden, lead investigator of the AIM-HIGH trial, for his perspective on niacin and other HDL-modifying therapies.


December 20th, 2012

HPS2-THRIVE: No Benefit, Signal of Harm for Niacin Therapy

The largest-ever study of niacin has failed to show a clinical benefit of niacin and even found a strong signal of harm. Merck announced today that the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study did not meet its primary endpoint. In that study, the combination of a statin and Merck’s niacin compound, Tredaptive, a combination of extended-release niacin and […]